Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors
Share
Why It Matters
Cellectar's cancer medicine showed strong results in a small patient study. This hints the company might be moving closer to getting the medicine approved by regulators.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.